

## Total Synthesis of the 2,6-Sialylated Immunoglobulin G Glycopeptide Fragment in Homogeneous Form

Ping Wang,<sup>†</sup> Jianglong Zhu,<sup>†</sup> Yu Yuan,<sup>†</sup> and Samuel J. Danishefsky<sup>\*,†,‡</sup>

Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10065, and Department of Chemistry, Columbia University, Havemeyer Hall, 3000 Broadway, New York, New York 10027

Received August 24, 2009; E-mail: s-danishefsky@ski.mskcc.org

Carbohydrate domains mediate the stability, folding, and biological activity of glycoproteins.<sup>1</sup> Quality investigations into the impact of specific glycosylation patterns are complicated by formation of horrific mixtures of difficult-to-separate glycoforms. A major program underway in our laboratory seeks to address the challenge of obtaining single glycoforms of biologics through the de novo chemical synthesis of homogeneous glycopeptides and glycoproteins of established therapeutic value.<sup>2</sup>

Accordingly, we became interested in monomeric immunoglobulin G (IgG) purified from intravenous immunoglobulin (IVIG). This therapeutically valuable anti-inflammatory agent is commonly employed in the treatment of autoimmune disorders, such as rheumatoid arthritis and immune thrombocytopenia. The biological activity of IVIG derives from its Fc fragment, which presents a biantennary tridecasaccharide attached through an N-linkage to the Asn<sup>297</sup> residue. Recently, Ravetch and co-workers discovered the critical role of the terminal 2,6-linked sialic acids of the glycan in mediating the anti-inflammatory activity of IVIG.<sup>3</sup> Although the IVIG glycan is biosynthesized as a heterogeneous mixture containing both 2,3- and 2,6-sialylated carbohydrate domains, only the Fc fragment possessing the 2,6-sialylated glycoform demonstrates appreciable anti-inflammatory activity in arthritic mice. Moreover, an IVIG Fc fragment possessing exclusively 2,6-sialic acid linkages was shown to be 10-fold more active in suppressing inflammation in mice than was an Fc fragment isolated from IVIG (containing both 2,6- and 2,3-linkages). These results suggest that an Fc peptide fragment presenting a homogeneous 2,6-sialylated glycan domain (e.g., **1**) could be more potent and effective than the heterogeneous mixture currently employed in clinical settings.

We describe herein the chemical synthesis of the homogeneous tridecasaccharide **1** possessing terminal 2,6-sialic acid linkages. We further describe the aspartylation of **1** with a peptide domain, thereby demonstrating the ability to convert it into a glycopolypeptide (see **28**). Accordingly, glycopeptidic constructs corresponding to the carbohydrate domain of IgG can now be synthesized and screened.

The power of prioritized strategic bond disconnection as a means of guiding synthetic analysis, formalized by the Corey school,<sup>4</sup> is well-appreciated by students of chemical synthesis of complex target systems. Less well appreciated is a type of pattern recognition analysis that can be very helpful in devising total synthesis programs directed toward biologic-level oligosaccharides.<sup>5</sup> System **1** constitutes a significant challenge to chemical synthesis. In particular, the 13-mer contains an often troublesome L- $\alpha$ -fucosyl ring (ring 5) branching from the “reducing-end” GlcNAc of the terminal

chitobiose (rings 1 and 2). It also presents the complex  $\beta$ -mannose linkage joining a  $\beta$ -mannose (ring 3) to the chitobiose core system. The  $\beta$ -mannoside (ring 3) in turn is linked in a biantennary fashion from its C<sub>3</sub> and C<sub>6</sub> hydroxyls to two  $\alpha$ -linked mannosides (see rings 6 and 7). The C<sub>2</sub> hydroxyls of these mannosides are linked in a  $\beta$ -fashion to two lactosamines, joined in 2,6-linkages to sialic acids (see rings 8–13). The  $\beta$ -linked mannose (ring 3) is also joined at its equatorial C<sub>4</sub> oxygen in a  $\beta$ -linkage to a GlcNAc residue (see ring 4).

On the basis of earlier literature in this general area,<sup>6</sup> it seemed likely that the most demanding phase of the synthesis would involve the attachment of the two trisaccharide ensembles, rings 8–10 and rings 11–13, to their respective axial hydroxyl acceptor sites in ring 6 and ring 7. Looming particularly difficult was the prospect of introducing additional appendages at the interior C<sub>2</sub> axial hydroxyl of ring 7. Indeed, it was our hope for conciseness to conduct simultaneous azaglycosylations at both of these two acceptor sites to introduce  $\beta$ -glucosamine donor residues (see rings 8 and 11). These rings would in turn be joined at their C<sub>4</sub> equatorial hydroxyl groups via  $\beta$ -linkages to C<sub>6</sub>-sialylated galactosyl donors. Ring 7 emanates from the particularly hindered C<sub>3</sub> hydroxyl site of ring 3 nestled between the glucosamine moiety at C<sub>4</sub>, the axial hydroxyl at C<sub>2</sub>, and the complex core substructure (rings 1 and 2). In fact, previous attempts to use the more exposed C<sub>6</sub> hydroxyl of ring 3 as a viable acceptor site met with only the slightest of success. No glycosylation at all had been achieved at the much more hindered secondary hydroxyl acceptor site at C<sub>3</sub> of ring 3. Indeed, the key breakthrough involved the use of a phenylsulfamido function on the future ring 4 (see the \* in compound **4**) to allow for introduction of rings 5, 6, and 7 (see below).



In Scheme 1, by focusing on key building blocks, we recapitulate the strategic analysis that eventually achieved success. Thus, as shown, we envisioned reaching tetrasaccharide **4** through coupling of trisaccharide **5** with sulfonamide donor **6**.<sup>7</sup> As noted, the presence of the sulfonamide functionality on diol **4** would prove to be key to the efficient installation of the “wing” mannose and fucose units, furnishing core heptasaccharide **3**.<sup>8</sup> Elongation of the mannose units with a  $\beta$ -GlcNAc donor would yield the nonasaccharide, **2**, which would finally be subjected to diglycosylation with disaccharide **10**, affording the target compound, **1**. Happily, in this synthetic analysis, we were able to revisit the chemistry developed in connection with our longstanding glycal assembly program.<sup>9</sup>

Our synthesis of key intermediate **2** commenced with the known monosaccharides **11**<sup>10</sup> and **12** (Scheme 2). Glycosylation of **12** with donor **11** through exposure to NIS/TMSOTf<sup>11</sup> under sonication conditions proceeded rapidly to afford the disaccharide in 82% yield.<sup>12</sup> Subsequent saponification furnished acceptor **13**. The latter was then glycosylated with donor **14**,<sup>13</sup> which gave trisaccharide **15** with good selectivity ( $\beta/\alpha = 7:1$ ). The  $\beta$ -isomer was isolated

<sup>†</sup> Sloan-Kettering Institute for Cancer Research.

<sup>‡</sup> Columbia University.


## Scheme 1. Synthetic Strategy Toward Tridecasaccharide 1

Scheme 2. Synthesis of Intermediate 2<sup>a</sup>

<sup>a</sup> Key: (a) 1. NIS/TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, sonication, 82%; 2. NaOMe/MeOH, 92%. (b) **14**, Tf<sub>2</sub>O, DTBP, CH<sub>2</sub>Cl<sub>2</sub>, 65%. (c) 1. Zn(OTf)<sub>2</sub>/EtSH, CH<sub>2</sub>Cl<sub>2</sub>, 75%; 2. BzCl, Py, CH<sub>2</sub>Cl<sub>2</sub>, 93%. (d) **6**, MeOTf, DTBP, CH<sub>2</sub>Cl<sub>2</sub>, 92% ( $\beta/\alpha = 2.7:1$ ). (e) 1. NaOMe/MeOH, 83%; 2. TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, 93% (CAN, 66%). (f) **7**, NIS/TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, 90%. (g) HF/Py, THF, sonication, 88%. (h) **8**, Cp<sub>2</sub>Zr(OTf)<sub>2</sub>, DTBP, toluene/THF, 93% ( $\alpha/\beta = 12:1$ ). (i) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, Py/AcOH (1:1), CH<sub>2</sub>Cl<sub>2</sub>, 93%. (j) **9**, toluene, BF<sub>3</sub>·OEt<sub>2</sub>. (k) K<sub>2</sub>CO<sub>3</sub>, MeOH, 52%.


in 65% yield. Following removal of the benzylidene acetal<sup>14</sup> and selective benzylation of the resulting 4,6-diol, compound **5** was in hand. MeOTf-promoted<sup>15</sup> glycosylation with glucosamine building block **6** afforded a 92% yield of **16** ( $\beta/\alpha = 2.7:1$ ).

Sequential removal of the benzoate and PMB protecting groups of tetrasaccharide **16** afforded 3,6-diol **4** in 77% yield over two steps. Twofold glycosylation of **4** was accomplished with an excess of donor **7** and NIS/TMSOTf, providing hexasaccharide **17** in 90% yield. The TBDPS group was cleaved upon exposure to HF/Py (88% yield). To the resultant free hydroxyl group was appended fluoride donor **8**<sup>16</sup> under Cp<sub>2</sub>Zr(OTf)<sub>2</sub> mediation<sup>17</sup> to afford compound **19** in 93% yield and excellent selectivity ( $\alpha/\beta = 12:1$ ). Following removal of the levulinoyl protecting group, intermediate **3** was in hand. BF<sub>3</sub>·OEt<sub>2</sub>-promoted diglycosylation of **3** was achieved through the use of excess donor **9**.<sup>18</sup> Finally, removal of the chloroacetate groups on the glucosamine units provided the target nonasaccharide **2** in 52% yield over two steps.

Scheme 3. Synthesis of Disaccharide Donor 10<sup>a</sup>

<sup>a</sup> Key: (a) TMSOTf, toluene/THF, 81%. (b) 1. PhI(OAc)<sub>2</sub>/BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; 2. Py, Ac<sub>2</sub>O, 89%. (c) 1. N<sub>2</sub>H<sub>4</sub>·AcOH, DMF; 2. DAST, CH<sub>2</sub>Cl<sub>2</sub>, 82%.

Having completed the synthesis of compound **2**, we then turned to the assembly of disaccharide donor **10** (Scheme 3). In the event, coupling of phosphite **21**<sup>19</sup> and galactal **22**<sup>20</sup> proceeded smoothly to afford disaccharide **23** with good selectivity ( $\alpha/\beta = 11:1$ ). The predominant  $\alpha$  isomer was isolated in 81% yield. Oxidation of **23** with PhI(OAc)<sub>2</sub><sup>21</sup> followed by acetylation furnished disaccharide

**Scheme 4.** Synthesis of Tridecasaccharide **1** and Glycopeptide **28**<sup>a</sup>

<sup>a</sup> Key: (a)  $\text{BF}_3 \cdot \text{OEt}_2$ ,  $\text{CH}_2\text{Cl}_2$ , 54%. (b) 1.  $\text{NaOMe/MeOH}$ ,  $\text{THF/MeOH/H}_2\text{O}$ ; 2.  $\text{H}_2\text{NCH}_2\text{CH}_2\text{NH}_2$ ; 3.  $\text{Ac}_2\text{O}$ ,  $\text{Et}_3\text{N}$ ,  $\text{MeOH}$ ; 4.  $\text{Na}$ ,  $\text{NH}_3(\text{l})$ ; 5.  $\text{Ac}_2\text{O}$ ,  $\text{NaHCO}_3$ ,  $\text{H}_2\text{O}$ , 52%. (c)  $\text{NH}_4\text{HCO}_3$ ,  $\text{H}_2\text{O}$ . (d) Peptide **27**, HATU, DIEA, DMSO, 20% yield over two steps. **27**:  $\text{AcHN-Gly-Tyr-Phe-Leu-Val-Asp-Ser-Ser-Gly-Pro-CO}_2\text{Me}$ .

**24** in one pot.<sup>22</sup> Finally, deprotection of the anomeric acetate was accomplished through exposure to hydrazine acetate, providing the hemiacetal, which was further reacted with DAST to afford the target fluoride donor **10**.

With the two component pieces in hand, we now turned our attention to the completion of the tridecasaccharide synthesis. As outlined in Scheme 4,  $\text{BF}_3 \cdot \text{OEt}_2$ -mediated coupling of excess amounts of donor **10** with **2** provided mainly tridecasaccharide **25** (54% yield) along with a small amount of monocoupled product. The global deprotection of **25** was accomplished in five steps, as shown. First, the methyl ester and acetyl groups were removed using excess  $\text{NaOMe}$ . Next, the phthalimide groups were cleaved, and the resultant free amines were acetylated. We were pleased to find that the 25 benzyl groups and the sulfonamide group could be efficiently cleaved upon exposure to sodium in liquid ammonia.<sup>23</sup> Selective acetylation was accomplished through treatment with acetic anhydride in saturated  $\text{NaHCO}_3$ , affording **1**.

Finally, we examined the merger of tridecasaccharide **1** with a peptide domain and found that exposure of **1** to Kochetkov conditions<sup>24</sup> provided **26** (Scheme 4). Aspartylation of **26** with **27** provided the target glycopeptide **28**, albeit in modest yield.

In summary, we have synthesized the homogeneous 2,6-sialylated tridecasaccharide of the Fc sector of IVIG and successfully coupled the carbohydrate with a peptide domain to provide a glycopeptide adduct (**28**). The merger of **1** with appropriate Fc-derived peptide fragments and the results of biological evaluations of the glycopeptides will be reported in due course.

**Acknowledgment.** Support was provided by the NIH (CA28824 to S.J.D.). We thank Dr. George Sukenick, Hui Fang, and Sylvi Rusli of SKI's NMR core facility for mass spectral and NMR analysis; Rebecca Wilson for editorial assistance; and Dana Ryan for assistance with the preparation of the manuscript.

**Supporting Information Available:** Experimental procedures, characterization, and copies of spectral data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- (1) (a) Connor, S. E. O.; Imperiali, B. *Chem. Biol.* **1996**, *3*, 803. (b) Kobata, A. *Acc. Chem. Res.* **1993**, *26*, 319. (c) Feizi, T. *Nature* **1985**, *314*, 53.
- (2) For a review of glycoprotein synthesis, see: (a) Davis, B. J. *Chem. Rev.* **2002**, *102*, 579. Though unrelated to our current effort, dramatic advances have been made in the field of enzymatic glycoprotein synthesis. See: (b) Gamblin, D. P.; Scanlan, E. M.; Davis, B. J. *Chem. Rev.* **2009**, *109*, 131. For recent glycoprotein synthetic efforts from our laboratory, see: (c) Kan, C.; Trzupke, J. D.; Wu, B.; Wan, Q.; Chen, G.; Tan, Z.; Yuan, Y.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2009**, *131*, 5438. (d) Yuan, Y.; Chen, J.; Wan, Q.; Tan, Z.; Chen, G.; Kan, C.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2009**, *131*, 5432. (e) Tan, Z.; Shang, S.; Halkina, T.; Yuan, Y.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2009**, *131*, 5424. (f) Nagorny, P.; Fasching, B.; Li, X.; Chen, G.; Aussedat, B.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2009**, *131*, 5792.
- (3) (a) Anthony, R. M.; Nimmerjahn, F.; Ashline, D. J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, J. V. *Science* **2008**, *320*, 373. (b) Kaneko, V.; Nimmerjahn, F.; Ravetch, J. V. *Science* **2006**, *313*, 670.
- (4) Corey, E. J.; Cheung, X.-M. *The Logic of Chemical Synthesis*; Wiley-Interscience: New York, 1995.
- (5) Wilson, R. M.; Danishefsky, S. J. *J. Org. Chem.* **2007**, *72*, 4293.
- (6) (a) Yamazaki, F.; Nukada, T.; Ito, Y.; Sato, S.; Ogawa, T. *Tetrahedron Lett.* **1989**, *33*, 4417. (b) Yamazaki, F.; Sato, S.; Nukada, T.; Ito, Y.; Ogawa, T. *Carbohydr. Res.* **1990**, *201*, 31. (c) Paulsen, H.; Heume, M.; Nurnberger, H. *Carbohydr. Res.* **1990**, *200*, 127. (d) Weiler, S.; Schmidt, R. R. *Tetrahedron Lett.* **1998**, *39*, 2299. (e) Unverzagt, C. *Angew. Chem.* **1997**, *109*, 2078. (f) Eller, S.; Schuberth, R.; Gundel, G.; Seifert, J.; Unverzagt, C. *Angew. Chem., Int. Ed.* **2007**, *46*, 4173. (g) Paulsen, H. *Angew. Chem., Int. Ed.* **1990**, *29*, 823. For syntheses of selected complex bisected glycans, also see: (h) Jonke, S.; Liu, K. G.; Schmidt, R. R. *Chem.—Eur. J.* **2006**, *12*, 1274. (i) Matsuo, I.; Wada, M.; Manabe, S.; Yamaguchi, Y.; Otake, K.; Kato, K.; Ito, Y. *J. Am. Chem. Soc.* **2003**, *125*, 3402.
- (7) Griffith, D. A.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1990**, *112*, 5811.
- (8) Our initial efforts to elongate the heptasaccharide in the presence of an *N*-Phth functionality were unsuccessful, presumably because of the steric bulk of the phthalimide group. The sulfonamide-protected heptasaccharide was much more amenable to elongation.
- (9) Danishefsky, S. J.; Bilodeau, M. T. *Angew. Chem., Int. Ed.* **1996**, *35*, 1380.
- (10) Geeta, S.; Ole, H. J. *Carbohydr. Chem.* **1991**, *10*, 927.
- (11) Mootoo, D. R.; Konradson, P.; Udodong, U.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1988**, *110*, 5583.
- (12) Deng, S.; Gangadharmath, U.; Chang, C. J. *Org. Chem.* **2006**, *71*, 5179.
- (13) Crich, D.; Sun, S. *Tetrahedron* **1998**, *54*, 8321.
- (14) Nicolau, K. C.; Veale, C. A.; Hwang, C. K.; Hutchinson, J.; Prasad, C. V. C.; Ogilvie, W. W. *Angew. Chem., Int. Ed.* **1991**, *30*, 299.
- (15) Seeberger, P. H.; Beebe, X.; Sukenick, G. D.; Pochapsky, S.; Danishefsky, S. J. *Angew. Chem., Int. Ed.* **1997**, *36*, 491.
- (16) Wu, B.; Tan, Z.; Chen, G.; Chen, J.; Hua, Z.; Wan, Q.; Ranganathan, K.; Danishefsky, S. J. *Tetrahedron Lett.* **2006**, *47*, 8009.
- (17) Allen, J. R.; Allen, J. G.; Zhang, X.; Williams, L. J.; Zatorski, A.; Ragupathi, G.; Livingston, P. O.; Danishefsky, S. J. *Chem.—Eur. J.* **2000**, *6*, 1366.
- (18) Unverzagt, C. *Chem.—Eur. J.* **2003**, *9*, 1369.
- (19) Bhattacharya, S. K.; Danishefsky, S. J. *J. Org. Chem.* **2000**, *65*, 144.
- (20) Chen, X. T.; Sames, D.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1998**, *120*, 7760.
- (21) (a) Shi, L.; Kim, Y.-J.; Gin, D. Y. *J. Am. Chem. Soc.* **2001**, *123*, 6939. (b) Plante, O. J.; Palmacci, E. R.; Andrade, R. B.; Seeberger, P. H. *J. Am. Chem. Soc.* **2001**, *123*, 9545. (c) Hanashima, S.; Castagner, B.; Esposito, D.; Nokami, T.; Seeberger, P. H. *Org. Lett.* **2000**, *2*, 3881.
- (22) Hanashima, S.; Castagner, B.; Esposito, D.; Nokami, T.; Seeberger, P. H. *Org. Lett.* **2007**, *9*, 1777.
- (23) (a) Iserloh, U.; Dudkin, V.; Wang, Z.; Danishefsky, S. J. *Tetrahedron Lett.* **2002**, *43*, 7027. (b) Wang, Z.-G.; Warren, J. D.; Dudkin, V. Y.; Zhang, X.; Iserloh, V.; Visser, M.; Eckhardt, M.; Seeberger, P. H.; Danishefsky, S. J. *Tetrahedron* **2006**, *62*, 4954.
- (24) Cohen-Anisfeld, S. T.; Lansbury, P. T. *J. Am. Chem. Soc.* **1993**, *115*, 10531.

JA907136D